Neurotech International Limited (ASX:NTI)

Market Cap	15.81M -39.7%
Revenue (ttm)	7.07M +8,687.8%
Net Income	-3.85M
EPS	-0.00
Shares Out	1.32B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	478,177
Open	0.0120
Previous Close	0.0120
Day's Range	0.0120 - 0.0120
52-Week Range	0.0100 - 0.0290
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 24, 2026

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technolog...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In fiscal year 2025, Neurotech International's revenue was 2.44 million, a decrease of -23.07% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.